Wells Fargo cuts Bristol-Myers Squibb stock price target on LOE concerns

Wells Fargo cut its Bristol-Myers Squibb price target to $60 from $65 and maintained Equal Weight, citing Eliquis’s expected loss of exclusivity in some major EU markets in mid-November and questions about Admilparant efficacy and safety. Management reaffirmed Eliquis guidance and said Breyanzi growth remains strong; the Admilparant trial liver-toxicity event was in the high-dose arm and an independent committee deemed it unlikely to be drug-related. The article also notes prior Q3 results above expectations and raised full-year revenue guidance of $49.75B–$50.25B, alongside a 4.1% dividend yield and 17 recent analyst earnings revisions downward.

Analysis

The key risk is not the analyst target cut itself; it is whether BMY’s newer products can replace the cash flows exposed to Eliquis generic entry. The European launch is a regional event, not a global cliff, and the realized hit depends on market-by-market generic uptake, contracting, and BMY’s and Pfizer’s exposure. A rapid decline is plausible, but the article provides no regional revenue contribution with which to size it. Opdivo’s inventory reversal can also make the next quarter’s reported growth look weaker or stronger than underlying demand; track sell-through and subsequent guidance rather than extrapolating one quarter.

Breyanzi offers an offset, but cell-therapy growth is execution- and capacity-dependent and faces competition from Gilead’s CAR-T portfolio. Admilparant remains a clinical uncertainty: the committee’s view on one liver event does not settle prescriber perception or the efficacy question. The reported 50–70mL FVC estimate is Wells Fargo’s interpretation, not established trial efficacy. Readouts in late 2026/early 2027 are near-term catalysts; broader portfolio replacement is a multi-year test.

The contrarian case is that the market may overweight a known, geographically limited LOE while underweighting the potential for newer products to offset it. Conversely, an earnings beat and raised guidance do not prove durable replacement growth. The article’s chronology is inconsistent, describing Q3 results as already reported while also citing forecasts for Q3 2026; verify the source and current guidance before trading. The $60 target is not an independent valuation anchor.

Key Decisions for Investors

• Avoid chasing the target cut with an outright short at the cited price: known LOE risk may be partly discounted, while recent guidance commentary and the dividend may cushion the downside. Treat BMY as market-weight pending better exposure data.
• For a relative-value expression, consider an underweight in BMY versus a diversified pharma basket, sized modestly and reviewed after the first EU generic-launch data. The thesis is relative earnings uncertainty, not a sector-wide bearish call.
• Before adding or shorting, verify Eliquis revenue by geography and partner economics, generic launch timing and uptake, and whether Opdivo’s inventory unwind is offset by end-market demand. Reassess if reported growth and guidance show newer products consistently replacing the lost sales.
• Monitor Breyanzi demand, capacity and competitive trends, plus Admilparant safety disclosures and the late-2026/early-2027 trial readouts. A meaningful efficacy signal without a safety setback would weaken the bearish thesis; a guidance reduction or evidence of faster-than-expected EU erosion would strengthen it.